

BEXIMCO PHARMACEUTICALS LIMITED

17, DHANMONDI, ROAD NO. 2,
DHAKA-1205

PRICE SENSITIVE INFORMATION

This is for information of all concerned that the Board of Directors of the Company in their meeting held on 28 October, 2019 at 3.30 p.m. has approved the audited Financial Statements for the year ended on 30 June, 2019 and took the following decisions:

1. Recommended Dividend : 15% Cash Dividend.
2. Record date : 25 November, 2019.
3. Date & Time of 43rd AGM : 21 December, 2019 at 10.30 A.M.
4. Venue of 43rd AGM : Beximco Industrial Park, Sarabo, Kashimpur, Gazipur.

Comparative Financial Disclosures:

Beximco Pharmaceuticals Limited (Stand-alone)

Particulars	Year ended 30 June, 2019	Year ended 30 June, 2018
Net Profit after Tax	Tk.3,023,500,974	Tk.2,558,971,263
Earnings Per Share (EPS)	Tk.7.46	Tk.6.31
Net Asset Value (NAV)	Tk.29,600,843,240	Tk.27,104,389,931
Net Asset Value per share (NAVPS)	Tk.72.99	Tk.66.83
Net Operating Cash Flow Per Share (NOCFPS)	Tk.6.72	Tk.4.56

Beximco Pharmaceuticals Limited and its Subsidiaries (Consolidated)

Particulars	Year ended 30 June, 2019	Year ended 30 June, 2018
Net Profit after Tax	Tk.3,040,402,954	Tk.2,532,654,301
Earnings Per Share (EPS)	Tk.7.48	Tk.6.25
Net Asset Value (NAV)	Tk.29,588,317,284	Tk.27,081,962,616
Net Asset Value per share (NAVPS)	Tk.72.96	Tk.66.78
Net Operating Cash Flow Per Share (NOCFPS)	Tk.7.30	Tk.4.49

By order of the Board,

Sd/-

(MOHAMMAD ASAD ULLAH, FCS)

EXECUTIVE DIRECTOR & COMPANY SECRETARY

Dated: 28 October, 2019